ImmuneRegen Responds to Canadian Defense Ministry With Possible Treatment for Anthrax

SCOTTSDALE, Ariz. -- Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that it has submitted its final response to an invitation to participate in the Canadian Defense Ministry's "Universal Protectants Proposal." 

The goal of this program is to find a "universal" treatment for chemical, biological, radiological, and nuclear (CBRN) threats, such as anthrax or dirty bombs.  The Proposal is under the auspices of the Ottawa and Suffield provincial branches of the Canadian Defense Ministry's R & D program, The CBRN Research and Technology Initiative (CRTI).

"We believe Radilex to be one of the best universal protective candidates available against CBRN attacks, since our methods of action do not simply neutralize the attacking agent, but actually increase immune system activity, thereby allowing the body's own immune system to attack and overcome the CBRN agent," commented Dr. Mark Witten, co-founder and chief ccientific officer of ImmuneRegen Biosciences, Inc.  "We believe it is crucial in the war on terrorism that Radilex be utilized as a possible treatment for anthrax exposure in emergency events such as the recent detection of anthrax in the Pentagon mail facility on March 14."

On March 11, ImmuneRegen submitted a formal proposal for inclusion in the Universal Protectants Proposal respective to the company's compound Radilex, currently in development for treating the negative and possibly deadly effects of anthrax, Acute Radiation Sickness (ARS), and Acute Respiratory Distress Syndrome (ARDS)

Recent testing of Radilex using Total Body Irradiation (TBI) showed a 100 percent

survival rate among irradiated mice treated with Radilex Post Lethal Exposure

(PLE).  ImmuneRegen also recently responded to a Request for Information (RFI)

from the U.S. Department of Health and Human Services (DHHS) regarding

potential therapeutics for the treatment for ARS.

Source: ImmuneRegen BioSciences